James Proulx
Pfizer (United States)(US)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Research on Leishmaniasis Studies, Dermatology and Skin Diseases, Retinoids in leukemia and cellular processes, Asthma and respiratory diseases
Most-Cited Works
- → Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial(2015)390 cited
- → Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials(2015)316 cited
- → Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial(2014)144 cited
- → Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis(2016)144 cited
- → Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial(2010)62 cited
- → THU0187 Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials(2016)
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial(2015)